Terms ending in 2027
Every in-force patent on Ambrx, Inc.'s record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,175,083 | Novel Antigen-Binding Polypeptides and Their Uses In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 7,632,924 | Novel Antigen-Binding Polypeptides and Their Uses In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 7,632,823 | Compositions of Trna and Uses Thereof In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 7,919,591 | Modified Human Plasma Polypeptide or FC Scaffolds and Their Uses In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 9,868,972 | Hybrid Suppressor Trna for Vertebrate Cells In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 8,008,456 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides In force · High confidence | Ambrx, Inc. | In force | High confidence | |
| US 8,906,676 | Modified Human Four Helical Bundle Polypeptides And Their Uses In force · High confidence | Ambrx, Inc. | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.